Horizon Space Acquisition

Horizon Space Acquisition II Corp. was a special purpose acquisition company (SPAC) that completed a business combination with SL Bio Ltd. in June 2026, forming the combined entity SL Science Holding Limited (NASDAQ: SLBT). SL Science is a clinical-stage biomedical company specializing in the development of standardized, scalable cellular and gene therapies for cancer treatment and regenerative medicine. The company's proprietary platforms include next-generation immunotherapies, such as Armed-T and Gamma Delta T (GDT) cell technologies, targeting high-need indications like glioblastoma, pancreatic cancer, and blood cancers. Additionally, the company is advancing regenerative products utilizing cow milk-derived exosomes and plant extracts for tissue repair and skincare.